drugset
drugset / Trial / NCT03961698

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698 ↗

Phase 2 Unknown 91 enrolled Infinity Pharmaceuticals, Inc. Roche Pharma AG · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).

Timeline

Start
2019-12-17
Primary completion
2023-08-31
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 840 mg Intravenous
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous
Subject eganelisib Small molecule 20 mg Oral
Subject eganelisib Small molecule 30 mg Oral
Subject eganelisib Small molecule 40 mg Oral

Indications

breast cancer renal cell carcinoma